Povidone-Iodine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | E-Z SCRUB 201 | — | 1985-11-29 | fda.gov ↗ |
Trials 94 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT04457765 | Apr 2021 → Sep 2022 | — | Boston Medical Center | Withdrawn | No outcome recorded |
| Phase 0 | NCT04449965 | Jan → Aug 2021 | COVID-19 | St. Paul's Hospital, Canada | Terminated | No outcome recorded |
| Phase 0 | NCT04478019 | Jul 2020 → Jun 2022 | COVID-19 | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 0 | NCT02990013 | Dec 2018 → Dec 2019 | toxic dermatosis | University of Miami | Completed | No outcome recorded |
| Phase 0 | NCT04097613 | Jul 2017 → Apr 2019 | chronic rhinosinusitis | St. Paul's Hospital, Canada | Completed | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT06339294 | Jun → Dec 2023 | otomycosis | Rawalpindi Medical College | Completed | No outcome recorded |
| Phase 1 | NCT04761133 | Mar → Jul 2021 | respiratory tract infectious disorder | Alexandria University | Completed | No outcome recorded |
| Phase 1 | NCT04075526 | Oct 2019 → Jan 2024 | osteoarthritis | NYU Langone Health | Completed | No outcome recorded |
| Phase 1 | NCT04039126 | Jun 2019 → Dec 2020 | pleural neoplasm | University College Hospital, Ibadan | Unknown | No outcome recorded |
| Phase 1 | NCT02645617 | Mar → Sep 2016 | dental caries | Advantage Dental Services, LLC | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04347954 | Aug → Dec 2020 | COVID-19 | Stanford University | Completed | No outcome recorded |
| Phase 1/2 | NCT04510402 | Aug 2020 → Feb 2021 | COVID-19, iodine hypothyroidism | Brigham and Women's Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04371458 | Jul 2020 → Jul 2025 | thymoma | Yale University | Withdrawn | No outcome recorded |
| Phase 221 trials | ||||||
| Phase 2 | NCT06836271 | Mar → Apr 2025 overdue | prostate cancer | Hitit University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05696132 | Nov 2024 → Dec 2025 | methicillin-resistant staphylococcus aureus infectious disease | Nantes University Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT06616207 | Sep 2024 → Mar 2027 expected | gingivitis | University of Washington | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03749317 | Feb 2023 → Apr 2024 | viral conjunctivitis | IVIEW Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05816070 | Jan → Nov 2023 | bacterial conjunctivitis | IVIEW Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05546762 | Sep 2022 → Apr 2024 | pleural empyema | Alexandria University | Completed | No outcome recorded |
| Phase 2 | NCT05272254 | Sep 2022 → May 2027 expected | dental caries | University of Rochester | Recruiting | No outcome recorded |
| Phase 2 | NCT04947527 | Jun 2022 → Jun 2024 | dental caries | Advantage Silver Dental Arrest, LLC | Completed | No outcome recorded |
| Phase 2 | NCT05239598 | Feb → Jul 2022 | COVID-19 | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT04371965 | Sep → Oct 2020 | COVID-19 | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04549376 | Jul → Oct 2020 | COVID-19 | DR. MALA KHAN | Completed | No outcome recorded |
| Phase 2 | NCT04410159 | Jun 2020 | COVID-19 | Islamic Science University of Malaysia | Completed | No outcome recorded |
| Phase 2 | NCT04364802 | Apr 2020 → Jan 2022 | COVID-19 | Nikita Gupta | Completed | No outcome recorded |
| Phase 2 | NCT04253912 | Feb 2020 → Jan 2021 | common wart | Veloce BioPharma LLC | Unknown | No outcome recorded |
| Phase 2 | NCT03484507 | Jan 2018 → Nov 2022 | Acanthamoeba keratitis | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT03101371 | Oct 2017 → Feb 2019 | prosthesis-related infectious disease, urinary tract infection | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2 | NCT03082196 | Mar 2017 → May 2019 | dental caries | Advantage Dental Services, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04183231 | Nov 2016 → Feb 2017 | dental caries | Advantage Silver Dental Arrest, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02664220 | Apr 2016 → Mar 2018 | appendicitis | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2 | NCT02126709 | Jun → Dec 2014 | acne | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT00386958 | Nov 2002 → Jan 2006 | corneal ulcer | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05895773 | Jun → Nov 2023 | — | Menoufia University | Completed | No outcome recorded |
| Phase 314 trials | ||||||
| Phase 3 | NCT06363877 | Jun 2024 → Oct 2026 expected | — | Loma Linda University | Recruiting | No outcome recorded |
| Phase 3 | NCT06302335 | Jan 2023 → Dec 2027 expected | — | Hospital de Clinicas de Porto Alegre | Recruiting | No outcome recorded |
| Phase 3 | NCT05084378 | Mar 2022 → Aug 2024 | periprosthetic joint infection | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 3 | NCT05021315 | Sep 2021 → Sep 2022 | infective vaginitis, puerperal infection | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT04872686 | Apr → May 2021 | viral respiratory tract infection | DR. MALA KHAN | Completed | No outcome recorded |
| Phase 3 | NCT04446104 | May → Aug 2020 | COVID-19 | National University Hospital, Singapore | Completed | No outcome recorded |
| Phase 3 | NCT04048356 | Jul 2019 → Feb 2021 | female reproductive system disorder, pelvic organ prolapse, urinary tract infection | University of New Mexico | Completed | No outcome recorded |
| Phase 3 | NCT02998554 | Mar 2017 → May 2019 | viral conjunctivitis | Shire | Terminated | No outcome recorded |
| Phase 3 | NCT01531699 | Feb → Oct 2012 | infectious disease | Altacor Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01700803 | Jan → Apr 2012 | — | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT01321125 | Apr → Dec 2011 | infectious disease | University of Guanajuato | Completed | No outcome recorded |
| Phase 3 | NCT00950027 | Apr 2008 → Sep 2011 | — | Rennes University Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT00516399 | Mar 2008 → Sep 2010 | fungal keratitis | University of California, Los Angeles | Terminated | No outcome recorded |
| Phase 3 | NCT00500669 | Jun 2004 → Dec 2013 | skin infection, varicose disease | Royal Hobart Hospital | Terminated | No outcome recorded |
| Phase 427 trials | ||||||
| Phase 4 | NCT04200729 | Mar 2027 → Mar 2030 expected | appendicitis | The University of Texas Health Science Center, Houston | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07707063 | May 2026 → May 2027 expected | periodontitis | Military Hospital of Tunis | Recruiting | No outcome recorded |
| Phase 4 | NCT07474194 | Sep 2025 → Apr 2026 overdue | — | Beni-Suef University | Recruiting | No outcome recorded |
| Phase 4 | NCT05745467 | Jul 2024 → Jul 2025 | COVID-19 | University of Iowa | Withdrawn | No outcome recorded |
| Phase 4 | NCT04941131 | May → Jul 2023 | COVID-19 | King Abdulaziz University | Completed | No outcome recorded |
| Phase 4 | NCT05763602 | Sep 2022 → May 2026 overdue | — | Loreen Herwaldt | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05529173 | Sep 2022 → Nov 2023 | methicillin-resistant staphylococcus aureus infectious disease | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 4 | NCT05276687 | Sep 2022 → Mar 2024 | — | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT05049213 | Jun → Aug 2022 | COVID-19 | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05946005 | Dec 2021 → Apr 2022 | — | Hasanuddin University | Completed | No outcome recorded |
| Phase 4 | NCT05214196 | Sep → Dec 2021 | COVID-19 | Ataturk University | Completed | No outcome recorded |
| Phase 4 | NCT04981860 | Aug 2021 → Dec 2025 | bacterial conjunctivitis | University of Miami | Suspended | No outcome recorded |
| Phase 4 | NCT04517188 | Apr → Jul 2021 | COVID-19 | Halodine LLC | Unknown | No outcome recorded |
| Phase 4 | NCT04745663 | Feb → Apr 2021 | eye infectious disorder | Norwegian University of Science and Technology | Terminated | No outcome recorded |
| Phase 4 | NCT04210505 | Sep 2020 → Jan 2024 overdue | staphylococcus aureus infection | Marin L. Schweizer, PhD | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04146116 | Feb 2020 → Jun 2021 | — | University of Iowa | Completed | No outcome recorded |
| Phase 4 | NCT03757143 | Jan → Sep 2019 | — | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02975921 | Jul 2018 → Sep 2020 | congestive heart failure, pleural neoplasm | Yale University | Withdrawn | No outcome recorded |
| Phase 4 | NCT03385304 | Apr 2018 → Oct 2021 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 4 | NCT03447639 | Mar → Oct 2018 | prosthesis-related infectious disease, urinary tract infection | Corewell Health East | Terminated | No outcome recorded |
| Phase 4 | NCT03133312 | May → Dec 2017 | bacterial infectious disease | Metro Health, Michigan | Completed | No outcome recorded |
| Phase 4 | NCT02245334 | Oct 2014 → Oct 2015 | infectious disease, prostate disorder | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02032394 | Jul 2013 → Feb 2014 | bacteriuria, nosocomial infection, urinary tract infection | Mashhad University of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT01647347 | Aug 2012 → Jul 2013 | — | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT01437228 | Oct 2010 → Mar 2011 | endometritis | Erzincan Military Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00461656 | Sep 2009 → Dec 2012 | endophthalmitis, strabismus | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01179412 | Jul 2004 → Dec 2009 | viral conjunctivitis | Mahidol University | Completed | No outcome recorded |
| Phase not applicable18 trials | ||||||
| — | NCT07715409 | May 2027 expected | endometritis | Mohamed Mousa Mohamed Mousa | Not yet recruiting | No outcome recorded |
| — | NCT04341688 | Dec 2021 → Jun 2022 | COVID-19 | Aga Khan University | Unknown | No outcome recorded |
| — | NCT07470242 | Oct 2021 → Mar 2023 | chronic rhinosinusitis | Pusan National University Hospital | Completed | No outcome recorded |
| — | NCT05160623 | Aug 2021 → Dec 2022 | blepharitis | Shaare Zedek Medical Center | Unknown | No outcome recorded |
| — | NCT05175027 | May → Oct 2021 | — | Hisar Intercontinental Hospital | Completed | No outcome recorded |
| — | NCT06284174 | Jan 2021 → Dec 2024 overdue | — | National Cheng-Kung University Hospital | Recruiting | No outcome recorded |
| — | NCT04707742 | Jun 2020 → Sep 2021 | COVID-19 | FISABIO Foundation | Completed | No outcome recorded |
| — | NCT03432975 | Dec 2017 → Aug 2019 | periodontitis, chronic, adult | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Unknown | No outcome recorded |
| — | NCT02676791 | Feb 2016 → Sep 2021 | neoplasm of esophagus | Technical University Dresden | Completed | No outcome recorded |
| — | NCT02424357 | Jul 2015 → Jan 2016 | strabismus | University of Miami | Completed | No outcome recorded |
| — | NCT02027324 | Jun 2015 → Feb 2017 | — | Brigham and Women's Hospital | Withdrawn | No outcome recorded |
| — | NCT02216227 | Apr 2014 → Feb 2021 | — | VA Office of Research and Development | Completed | No outcome recorded |
| — | NCT02202577 | Mar 2014 → Jul 2016 | — | Case Western Reserve University | Completed | No outcome recorded |
| — | NCT01893060 | Jul 2013 → May 2014 | — | University of Virginia | Unknown | No outcome recorded |
| — | NCT01886001 | Nov 2012 → May 2013 | — | University of Virginia | Completed | No outcome recorded |
| — | NCT01560962 | Jan → Dec 2012 | blepharitis | Southern California Institute for Research and Education | Terminated | No outcome recorded |
| — | NCT01350713 | Jul 2011 → Jul 2012 | — | Meir Medical Center | Unknown | No outcome recorded |
| — | NCT00999427 | Oct 2009 → Apr 2011 | — | University of British Columbia | Completed | No outcome recorded |
Also used as a comparator or background therapy in 70 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03957291 Comparator | Aug 2019 → Aug 2022 | — | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT03571100 Comparator | May 2018 → May 2019 | age-related macular degeneration, retinal vein occlusion | Mid Atlantic Retina | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04393792 Comparator | May 2020 → Mar 2022 | COVID-19 | Hampshire Hospitals NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06906029 Comparator | Jul 2026 → Jul 2028 expected | abscess | University of Alabama at Birmingham | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04130451 Comparator | Oct → Dec 2019 | pneumothorax | Dow University of Health Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT04041856 Comparator | Aug → Oct 2019 | epidemic keratoconjunctivitis | Farabi Eye Hospital | Unknown | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02591251 Comparator | Oct 2015 → Mar 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02396329 Comparator | Jun 2014 → Jun 2015 | — | Ain Shams Maternity Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01577524 Comparator | Jan 2012 → Jun 2016 | — | Attabib, Najmedden, M.D. | Terminated | No outcome recorded |
| Phase 2 | NCT00845819 Comparator | Feb 2009 → Oct 2014 | chemotherapy-induced oral mucositis | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03640507 Comparator | Oct 2018 → May 2019 | — | Columbia University | Completed | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT07383402 Comparator | Mar 2026 → Dec 2027 expected | chronic rhinosinusitis | Amin Javer | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05127525 Comparator | Nov 2021 → Jan 2022 | angle-closure glaucoma, diabetic macular edema, occlusion of tributary of retinal vein | iRenix Medical, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03925155 Comparator | May 2020 → May 2022 | — | Montefiore Medical Center | Withdrawn | No outcome recorded |
| Phase 3 | NCT03700749 Comparator | Nov 2018 → Jul 2021 | — | University of Birmingham | Unknown | No outcome recorded |
| Phase 3 | NCT03004924 Comparator | Mar 2017 → Oct 2018 | bacterial conjunctivitis | Shire | Completed | No outcome recorded |
| Phase 3 | NCT02713074 Comparator | Oct 2016 → Mar 2017 | — | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT01481519 Comparator | Dec 2011 → Dec 2012 | viral conjunctivitis | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 3 | NCT01495117 Comparator | Oct 2011 → Oct 2014 | — | Seung Duk Lee | Completed | No outcome recorded |
| Phase 3 | NCT03062605 Comparator | May 2011 → Feb 2012 | dental caries | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 3 | NCT00692484 Comparator | Oct 2007 → Feb 2008 | — | C. R. Bard | Completed | No outcome recorded |
| Phase 3 | NCT00335088 Background | Jun 2006 → May 2007 | eye infectious disorder | HaEmek Medical Center, Israel | Unknown | No outcome recorded |
| Phase 3 | NCT00231153 Comparator | Aug 2005 → Jun 2008 | infectious disease | Cadence Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00290290 Comparator | Sep 2003 → May 2008 | — | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 422 trials | ||||||
| Phase 4 | NCT07044726 Comparator | Jun 2025 → May 2028 expected | bacterial urinary tract infection | University of Louisville | Recruiting | No outcome recorded |
| Phase 4 | NCT06705842 Comparator | Apr 2025 → Jun 2026 overdue | appendicitis | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Phase 4 | NCT06744907 Comparator | Jan → Nov 2025 overdue | — | Akron Children's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06282510 Comparator | Jan 2024 → Dec 2026 expected | candidiasis | Mary K Hayden | Recruiting | No outcome recorded |
| Phase 4 | NCT05919888 Comparator | Jun → Nov 2023 | periprosthetic joint infection | St. Louis University | Completed | No outcome recorded |
| Phase 4 | NCT05077592 Comparator | Sep → Dec 2021 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT04721457 Comparator | Jan → Mar 2021 | COVID-19 | King Abdulaziz University | Completed | No outcome recorded |
| Phase 4 | NCT04603794 Comparator | Oct → Nov 2020 | COVID-19 | Ohio State University | Unknown | No outcome recorded |
| Phase 4 | NCT03685604 Comparator | Sep 2018 → Jun 2020 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT03560193 Comparator | Sep 2018 → May 2022 | — | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03348917 Comparator | Dec 2017 → Jan 2018 | — | Mundipharma Manufacturing Pte Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT03349515 Comparator | Nov 2017 → Sep 2018 | strabismus | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 4 | NCT03305159 Comparator | Aug 2017 → Apr 2018 | — | Northwestern University | Completed | No outcome recorded |
| Phase 4 | NCT02527512 Comparator | Jul 2017 → Feb 2019 | necrotizing soft tissue infection | Boston Children's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03118232 Comparator | Apr 2017 → Oct 2023 | infectious disease | University of California, Irvine | Completed | No outcome recorded |
| Phase 4 | NCT03014778 Comparator | Jan 2017 → Dec 2018 | — | HaEmek Medical Center, Israel | Unknown | No outcome recorded |
| Phase 4 | NCT02693483 Comparator | Apr 2015 → Jun 2016 | puerperal infection | Ain Shams Maternity Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02116608 Comparator | Sep 2014 → Sep 2019 | tracheal disorder | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT02479347 Comparator | Mar 2013 → Sep 2016 | breast neoplasm, skin infection | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Completed | No outcome recorded |
| Phase 4 | NCT01919593 Comparator | Jan → Dec 2012 | bacterial infectious disease | Thammasat University | Completed | No outcome recorded |
| Phase 4 | NCT01313182 Comparator | Mar 2011 → Sep 2012 | — | Solventum US LLC | Completed | No outcome recorded |
| Phase 4 | NCT01184196 Comparator | Nov 2009 → Dec 2012 | osteoarthritis, knee | Central DuPage Hospital | Terminated | No outcome recorded |
| Phase not applicable24 trials | ||||||
| — | NCT07460297 Background | Apr 2025 → Jan 2028 expected | — | Jianyi Li | Enrolling by invitation | No outcome recorded |
| — | NCT07295210 Comparator | Dec 2024 → Dec 2025 | otomycosis | Mansoura University | Completed | No outcome recorded |
| — | NCT06400082 Comparator | Apr 2023 → Oct 2024 overdue | type 2 diabetes mellitus | Cairo University | Active not recruiting | No outcome recorded |
| — | NCT06595823 Comparator | Mar 2022 → Mar 2023 | — | Egymedicalpedia | Completed | No outcome recorded |
| — | NCT05422703 Background | Jan → Jun 2022 | temporomandibular joint dysfunction syndrome | Cairo University | Completed | No outcome recorded |
| — | NCT07155408 Background | Dec 2021 → May 2022 | androgenetic alopecia | Elif Asena KANTARCI | Completed | No outcome recorded |
| — | NCT05122169 Comparator | Dec 2021 → Dec 2025 | — | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT06950229 Comparator | Oct 2020 → Mar 2021 | — | Federal Teaching Hospital Abakaliki | Completed | No outcome recorded |
| — | NCT06936475 Comparator | Jun → Sep 2020 | endometritis | Federal Teaching Hospital Abakaliki | Completed | No outcome recorded |
| — | NCT04278950 Comparator | Feb 2020 → Feb 2021 | chronic rhinosinusitis | St. Paul's Hospital, Canada | Unknown | No outcome recorded |
| — | NCT03173053 Comparator | Feb 2018 → Oct 2021 | movement disorder, staphylococcus aureus infection | Radboud University Medical Center | Terminated | No outcome recorded |
| — | NCT03549702 Comparator | Jan 2017 → Feb 2018 | — | Ain Shams University | Completed | No outcome recorded |
| — | NCT02950246 Comparator | Nov 2016 → Jul 2018 | prosthesis-related infectious disease | Hôpital Raymond Poincaré | Unknown | No outcome recorded |
| — | NCT02868372 Comparator | Sep 2016 → Mar 2017 | skin infection | Assiut University | Unknown | No outcome recorded |
| — | NCT02472223 Comparator | Mar 2015 → Jun 2018 | viral conjunctivitis | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT02337972 Background | Jan → Dec 2015 | diabetic macular edema | Sheba Medical Center | Unknown | No outcome recorded |
| — | NCT04169919 Comparator | Nov 2014 → Oct 2018 | — | Minia University | Completed | No outcome recorded |
| — | NCT00896402 Comparator | Jul 2014 → Jan 2015 | infectious disease | Northwell Health | Withdrawn | No outcome recorded |
| — | NCT02391714 Background | Oct 2013 → Aug 2014 | — | University of New Mexico | Completed | No outcome recorded |
| — | NCT01898728 Comparator | Dec 2012 → Aug 2013 | cataract | McMaster University | Completed | No outcome recorded |
| — | NCT01472549 Comparator | Sep 2011 → Jun 2015 | — | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT01619137 Comparator | Aug 2011 → Oct 2012 | — | Aida Najafian | Unknown | No outcome recorded |
| — | NCT01216761 Comparator | May 2008 → Sep 2009 | bacterial infectious disease | University of Michigan | Completed | No outcome recorded |
| — | NCT02652325 Comparator | ? → Feb 2016 | — | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
Evidence & citations 31 cited values
Every value below carries the sentence it was read from. 171 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Povidone Iodine | “The purpose of this study is to see whether applying povidone iodine (PVI) to the noses of patients undergoing lower extremity (leg, ankle, or foot) orthopedic fixation...” NCT05763602 ↗162“Three antiseptics will be tested: 2% chlorhexidine gluconate in 70% isopropyl alcohol, 10% sodium hypochlorite and 10% povidone-iodine, each one will be applied on the surface...” NCT01321125 ↗ “A Phase 2, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution...” NCT03749317 ↗ “Participants instructed to instill 1 drop of SHP640 (Povidone-iodine \[PVP-I\] 0.6 percent \[%\] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID)...” NCT02998554 ↗ “In previous studies, povidone iodine (PVP-I), a widely used bactericidal antiseptic, and sodium fluoride (NaF), used to foster remineralization of enamel, were applied...” PMID 30938600 ↗ Apr 2018 “In order to assess the effect of Betadine (10% povidone-iodine) in the groin wound on infection rates and recurrence rates in patients undergoing primary varicose vein surgery...” NCT00500669 ↗ “MAIN RESULTS: We included 21 trials, reporting results for 7038 women evaluating the effects of vaginal cleansing (17 using povidone-iodine, 3 chlorhexidine, 1 benzalkonium...” PMID 32335895 ↗ Apr 2020 “Effect of oropharyngeal povidone-iodine preventive oral care on ventilator-associated pneumonia in severely brain-injured or cerebral hemorrhage patients: a multicenter,...” PMID 24105456 ↗ Jan 2014 “Vaginal preparation with povidone-iodine or chlorhexidine solution compared to saline or not cleansing immediately before cesarean delivery probably reduces the risk of...” PMID 30016540 ↗ Jul 2018 “Povidone iodine (PVP-I) is an alternative decolonization agent solutions and demonstrated rapid and superior bactericidal activity against MRSA in in vitro and ex vivo studies...” NCT05696132 ↗ “In this study, we compared the cutaneous antiseptic efficacy of 2% alcoholic chlorhexidine and povidone-iodine-alcohol for preventing the bacterial colonisation of PNCs in...” PMID 33285282 ↗ Dec 2020 “Povi-One (10% povidone-iodine) will be applied topically by the graduate student to all tooth surfaces at the consultation appointment (baseline) before the placement of fixed...” NCT06616207 ↗ “Although povidone-iodine (iodine) is the only Food and Drug Administration-approved vaginal antiseptic solution, there is a lack of comparative data evaluating alternatives.” PMID 34973179 ↗ Dec 2021 “the two-step mouth rinse (0.3% NaOCl followed by 10% Povidone Iodine) decreases the tooth causing germs better than the one-step mouth rinse (10% Povidone Iodine)” NCT03062605 ↗ “ChloraPrep (2% chlorhexadine gluconate and 70% isopropyl alcohol) is superior to Betadine (10% povidone iodine) in reducing incision site bacterial colony counts.” NCT01184196 ↗ “Drug Name: Povidone-Iodine Dosage form: 0.6% Povidone-Iodine Dosage: 2 puff 0.6% PVP-I in each nostril and 2 puff inside mouth Frequency and duration: Single” NCT04872686 ↗ “The purpose of this study to assess the clinical effectiveness and cost-effectiveness of povidone-iodine (PVI) irrigation in perforated appendicitis” NCT06705842 ↗ “Povidone-Iodine 5% (PI; brand name: Betadine® 5%; Alcon, Fort Worth, TX), the antiseptic placed on the ocular surface prior to each injection.” NCT05127525 ↗ “The effect on viral load was investigated by using 0.5% Povidone-iodine solution as an oral antiseptic for 30 seconds in 25 COVID-19 patients.” NCT05214196 ↗ “Povidone Iodine 0.5% plus glycyrrhizin acid 2.5 mg/ml as a nasal and an oropharyngeal spray (mint flavored) will be applied 4 times per day.” NCT05895773 ↗ “5 % vs. 1.25 % povidone-iodine (PI) as preoperative antiseptic prior to strabismus surgery in children as a prophylaxis of endophthalmitis.” NCT00461656 ↗ “About 100 patients women who underwent elective caesarian section with subcutaneous tissue irrigation with Povidone iodine 10% solution.” NCT06595823 ↗ “Vigorously rinse with 15 ml of the 1% povidone-iodine (PVP-I) (Betadine Mouthwash/Gargle; Avrio Health LP, Stamford, CT, USA) for 30 s” NCT04721457 ↗ “Group A will receive three drops of povidone-iodine ophthalmic solution in each eye, with the right eye to receive the drops first.” NCT03349515 ↗ “pyodine Povidone-iodine is a broad spectrum antiseptic for topical application in the treatment and prevention of wound infection.” NCT04130451 ↗ “INTERVENTIONS: One drop of 5% povidone-iodine directly over the sliding noose of the adjustable suture at the end of surgery.” PMID 27561000 ↗ Oct 2016 “Name: Repigel Active ingredient: Povidone iodine Dosage form: Liposomal hydrogel Administration route: Topical Strength: 3%” NCT02126709 ↗ “Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.” NCT01472549 ↗ “Povidone-Iodine (PVP-I), common usage in otolaryngology operation and topical therapy, showed high virucidal properties” NCT05049213 ↗ “Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19” NCT04371965 ↗ “Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis” NCT04200729 ↗ “Phase I/II Trial of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy Subjects” NCT04510402 ↗ “Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis” NCT04041856 ↗ “Povidone iodine vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.” NCT04048356 ↗ “Povidone Iodine 5% (povidone-iodine, Alcon) eye irrigation every day until the patients recovered” NCT04169919 ↗ “Povidone-iodine solution 5% w/w (0.5% available iodine) USP Patient Preoperative Skin Preparation” NCT01313182 ↗ “The side of the mouth receiving the subgingival irrigations of povidone iodine 10% (test group)” NCT03432975 ↗ “Addition of Povidone-Iodine to Fluoride Varnish for Dental Caries: A Randomized Clinical Trial.” PMID 32437626 ↗ May 2020 “The choice of antiseptic agent, povidone iodine or chlorhexidine gluconate, remains debated.” PMID 38884982 ↗ Aug 2024 “The antiseptic (Povidone-Iodine) is opened, and the surgical site is scrubbed with it.” NCT07474194 ↗ “0.2% Povidone-Iodine (Betadiene® by Aviro Health Inc./ Pyodine® by Brooks Pharma Inc.)” PMID 32928313 ↗ Sep 2020 “The active ingredients are 10% (w/v) Povidone-Iodine and 5% (w/v) Sodium Fluoride CAS.” NCT04947527 ↗ “Povidone-iodine 2% (Betadine© bucal 100 mg/ml) (Mylan Pharmaceuticals, S.L., Spain).” NCT04707742 ↗ “Hundred (100) ml of 5% povidone iodine was poured into a sterilized bowl (galipot).” NCT06950229 ↗ “Topical 2% Povidone-Iodine Gel (VBP-245) in Subjects With Verruca Vulgaris” NCT04253912 ↗ “5 mL of 1% povidone iodine solution delivered using a blunt-tip cannula” NCT07707063 ↗ “Povidone iodine (PVP-I) nasal irrigation at concentration of 0.4%” NCT04549376 ↗ “IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution” NCT05816070 ↗ “The active ingredients are Povidone Iodine and Sodium Fluoride” NCT02645617 ↗ “use 0.12% chlorhexidine or povidone iodine mouthwash daily” NCT05422703 ↗ “10 mL of Povidone-iodine 0.5% antiseptic mouth rinse” NCT05239598 ↗ “chemical sclerosants (ethanol and povidone iodine)” NCT06906029 ↗ “Pleural irrigation with 2% povidone iodine” NCT05546762 ↗ “pleural lavage using 10% povidone-iodine” NCT04371458 ↗ “Povidone Iodine (P-I) scrub and paint” NCT02202577 ↗ “povidone iodine and Hypochlorous acid” NCT05175027 ↗ “5% povidone iodine (PVI)-69% ethanol” NCT03757143 ↗ “SHP640 (povidone-iodine” NCT03004924 ↗ |
| Known as | Betadiene | “0.2% Povidone-Iodine (Betadiene® by Aviro Health Inc./ Pyodine® by Brooks Pharma Inc.)” PMID 32928313 ↗ Sep 2020 |
| Known as | Betadine | “250 ml solution of 2% povidone-iodine (i.e. 50 ml betadine in 200 ml saline) will be attached to the chest tube via a giving set and a 3-way tap and irrigated into the pleural...” NCT05546762 ↗14“with sterile water (water that has been treated to remove bacteria and living organisms) vs Betadine also known as Povidone-Iodine (a medical grade cleaning solution)” NCT07044726 ↗ “ChloraPrep (2% chlorhexadine gluconate and 70% isopropyl alcohol) is superior to Betadine (10% povidone iodine) in reducing incision site bacterial colony counts.” NCT01184196 ↗ “Povidone Iodine (Betadine®) irrigation of subcutaneous tissue prior to skin closure” NCT03549702 ↗ “Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)” NCT03348917 ↗ “0.2% Povidone-Iodine (BETADINE®) 10 ml gargle” NCT04341688 ↗ “0.35% povidone-iodine ("Betadine")” NCT02527512 ↗ “topical betadine (Povidone-iodine)” PMID 28549873 ↗ May 2017 |
| Known as | Betadine 5% | “Povidone-Iodine 5% (PI; brand name: Betadine® 5%; Alcon, Fort Worth, TX), the antiseptic placed on the ocular surface prior to each injection.” NCT05127525 ↗ |
| Known as | Betadine bucal 100 mg/ml | “Povidone-iodine 2% (Betadine© bucal 100 mg/ml) (Mylan Pharmaceuticals, S.L., Spain).” NCT04707742 ↗ |
| Known as | Betadine7.5% | “The patients will be subjected to povidone-iodine (Betadine7.5%, Phama Care) for vaginal cleaning before the laparoscopic surgery” NCT02591251 ↗1“The patients will be subjected to povidone-iodine (Betadine7.5%) for vaginal cleaning before office hysteroscopy” NCT02713074 ↗ |
| Known as | Bétadine alcoolique | “Groupe A: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) InsyteTM AutoguardTM BC Winged, BD” NCT03757143 ↗ |
| Known as | iodine | “Although povidone-iodine (iodine) is the only Food and Drug Administration-approved vaginal antiseptic solution, there is a lack of comparative data evaluating alternatives.” PMID 34973179 ↗ Dec 2021 |
| Known as | Isodine Solucion | “The arm is composed of 10 human volunteers to test 2% chlorhexidine gluconate in 70% isopropyl alcohol (ChloraPrep ®, Enturia, Texas, USA ), hypochlorite 10% of electrochemical...” NCT01321125 ↗ |
| Known as | IVIEW-1201 | “A Phase 2, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution...” NCT03749317 ↗1“IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution” NCT05816070 ↗ |
| Known as | Nasal Povidone Iodine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02216227 ↗ |
| Known as | P-I | “Povidone Iodine (P-I) scrub and paint” NCT02202577 ↗ |
| Known as | Polividon- iyot | “%10 Polivinilpirolidon iyot (Polividon- iyot” NCT01437228 ↗ |
| Known as | Polivinilpirolidon iyot | “%10 Polivinilpirolidon iyot (Polividon- iyot” NCT01437228 ↗ |
| Known as | Polyvinylpyrrolidone-Iodine | “a polyvinylpyrrolidone-iodine (PVP-I; povidone-iodine) and NaF topical varnish was superior to one containing only NaF in prevention of new dental caries lesions” PMID 32437626 ↗ May 20201“efficacy of topical 10% Polyvinylpyrrolidone-Iodine (PVPI) to prevent new caries lesions” NCT05272254 ↗ |
| Known as | Povi-One | “Povi-One (10% povidone-iodine) will be applied topically by the graduate student to all tooth surfaces at the consultation appointment (baseline) before the placement of fixed...” NCT06616207 ↗ |
| Known as | Povidine iodine | “with PI (povidine iodine) and AC (aqueous chlorhexidine).” NCT03957291 ↗ |
| Known as | povidon iodine | “Drug: povidon iodine” NCT02950246 ↗ |
| Known as | Povidone iodide | “Betadine (Povidone iodide) for reducing bacteria and patient discomfort in the eyes.” NCT04981860 ↗ |
| Known as | Povidone-iodine 0.5% (Betadine) (PVP-I) | “Povidone-iodine 0.5% (Betadine) (PVP-I)” NCT05214196 ↗ |
| Known as | Povidone-Iodine, USP 10% topical solution | “Povidone-Iodine, USP 10% topical solution” NCT00896402 ↗ |
| Known as | PROFEND | “This study aims to evaluate the real-world effectiveness of nasal povidone-iodine (PROFEND®) in a group of 50 patients at the University of Iowa.” NCT04146116 ↗ |
| Known as | PVI | “The purpose of this study is to see whether applying povidone iodine (PVI) to the noses of patients undergoing lower extremity (leg, ankle, or foot) orthopedic fixation...” NCT05763602 ↗6“superiority of chlorhexidine (CHG)-alcohol over povidone iodine (PVI)-alcohol, the two most common alcohol-based antiseptic solutions used worldwide, is controversial.” PMID 31213447 ↗ Jun 2019 “Povidone-iodine (PVI) is an antiseptic solution consisting of polyvinylpyrrolidone with water, iodide, and 1% available iodine.” NCT02664220 ↗ “Povidone-iodine (PVI) is a widely used antimicrobial agent.” NCT05160623 ↗ “intra-abdominal irrigation with povidone-iodine (PVI)” NCT04200729 ↗ “5% povidone iodine (PVI)-69% ethanol” NCT03757143 ↗ “povidone-iodine (PVI) irrigation” NCT06705842 ↗ |
| Known as | PVP-I | “Participants instructed to instill 1 drop of SHP640 (Povidone-iodine \[PVP-I\] 0.6 percent \[%\] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID)...” NCT02998554 ↗13“In previous studies, povidone iodine (PVP-I), a widely used bactericidal antiseptic, and sodium fluoride (NaF), used to foster remineralization of enamel, were applied...” PMID 30938600 ↗ Apr 2018 “Povidone iodine (PVP-I) is an alternative decolonization agent solutions and demonstrated rapid and superior bactericidal activity against MRSA in in vitro and ex vivo studies...” NCT05696132 ↗ “1.25% Povidone-Iodine (PVP-I) (also known as betadine) to be used pre-procedure in the operating room via irrigation into the nasal cavity to act as viricidal preparation for...” NCT04457765 ↗ “Povidone-iodine (PVP-I) has broad antimicrobial and anti-inflammatory properties, while budesonide is a corticosteroid commonly used intranasally to reduce sinonasal inflammation.” NCT07383402 ↗ “a polyvinylpyrrolidone-iodine (PVP-I; povidone-iodine) and NaF topical varnish was superior to one containing only NaF in prevention of new dental caries lesions” PMID 32437626 ↗ May 2020 “Vigorously rinse with 15 ml of the 1% povidone-iodine (PVP-I) (Betadine Mouthwash/Gargle; Avrio Health LP, Stamford, CT, USA) for 30 s” NCT04721457 ↗ “Povidone-Iodine (PVP-I), common usage in otolaryngology operation and topical therapy, showed high virucidal properties” NCT05049213 ↗ “Povidone-iodine (PVP-I) is a broad-spectrum antiseptic with activity against bacteria, fungi, and viruses.” NCT04364802 ↗ “Phase I/II Trial of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy Subjects” NCT04510402 ↗ “efficacy of topical 10% Polyvinylpyrrolidone-Iodine (PVPI) to prevent new caries lesions” NCT05272254 ↗ “Povidone iodine (PVP-I) nasal irrigation at concentration of 0.4%” NCT04549376 ↗ “7.5% Povidone-Iodine [PVP-I]” NCT03348917 ↗ “povidone-iodine (PVP-I)” NCT06302335 ↗ |
| Known as | PVP-Iodine | “SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension” NCT03004924 ↗ |
| Known as | pyodine | “pyodine Povidone-iodine is a broad spectrum antiseptic for topical application in the treatment and prevention of wound infection.” NCT04130451 ↗1“0.2% Povidone-Iodine (Betadiene® by Aviro Health Inc./ Pyodine® by Brooks Pharma Inc.)” PMID 32928313 ↗ Sep 2020 |
| Known as | Repigel | “Name: Repigel Active ingredient: Povidone iodine Dosage form: Liposomal hydrogel Administration route: Topical Strength: 3%” NCT02126709 ↗ |
| Known as | VBP-245 | “Topical 2% Povidone-Iodine Gel (VBP-245) in Subjects With Verruca Vulgaris” NCT04253912 ↗ |
| Action | Inhibit | “using Povidone-Iodine will reduce the the amount of virus in the nose and throat” NCT04393792 ↗ |
| Modality | Other / unclassified | “widely used as an antiseptic agent” NCT01577524 ↗ |
| Route | Topical | “treatment with topical povidone-iodine” NCT00231153 ↗ |